Theme: Exploring the new horizons to cure Hypertension & Cardiac diseases

Hypertension Meeting 2019

Renowned Speakers

Hypertension Meeting 2019

Following the success of the previous conferences, we are excited to announce that “7th International Conference on Hypertension & Healthcare” will be held during June 10-11, 2019  at the most beautifully crafted city of Helsinki, Finland. The theme of our conference is Exploring the new horizons to cure Hypertension & Cardiac diseases. Hypertension Meeting 2019 will be an international event focussing on the core knowledge and major advances in the ever-expanding field of Hypertension & Healthcare by attracting experts on a global scale.

This year, we also hope to bring together experiences from different countries and exchange their views, reinforce knowledge base, and learn new concepts. With the participation of outstanding international experts, we hope productive discussions would stimulate new creative ideas to translate new discoveries into better diagnosis and treatment of Cardiac Diseases. We sincerely invite you to join us in this very informative annual conference and collaborate in the global action in reducing the burden of Hypertension & cardiovascular diseases. Your presence will certainly add value to the conference and very much appreciated!

ME Conferences through its Open Access Initiative is committed to create real and reliable contributions to the scientific community. Conference Series Ltd organize 600+ Conferences once a year across USA, Europe & Asia with support from a thousand additional scientific societies and Publishes 400+ Open access journals that contains over 30000 eminent personalities, putative scientists as editorial board members.

Why to attend?? 

Encounter the target market with members from across the globe, committed to learn about hypertension treatment and management. This is the best opportunity to outreach the largest gathering of participants from around the world. Conduct presentations, distribute and update knowledge about the current situation of hypertension treatment and receive name recognition at this 2 days event. World-eminent speakers, most recent researches, latest treatment techniques and the advanced updates in Hypertension Management are the principal features of this conference.

Target Audience:

Our Organization would be privileged to welcome the:

  • Directors of Hypertension or related Programs or Associations
  • Heads, Deans and Professors of Hypertension or Cardiology departments
  • Scientists and Researchers organizers
  • Doctors
  • Medical Colleges
  • Writers
  • Healthcare professionals
  • Founders and Employees of the related companies
  • Clinical investigators
  • Hospitals and Health Services
  • Pharmaceutical companies
  • Laboratory members
  • Training institutions
  • Support organizers
  • Data Management Companies
  • Cardiologists training and education
  • Nurse and nursing education institutions

Track 1: Hypertension

Hypertension, also called high blood pressure is a long term medical condition in which the blood pressure in the arteries is frequently elevated. High blood pressure usually does not cause symptoms.  Long term high blood pressure is a main risk factor for coronary artery disease, stroke, heart failure, peripheral vascular disease, vision loss, and chronic kidney disease. It is classified as either primary (essential) high blood pressure or secondary high blood pressure. About 90–95% of cases are primary hypertension, caused due to nonspecific lifestyle and genetic factors. Lifestyle factors that increase the risk constitute excess salt, excess body weight, smoking, and alcohol. The rest 5–10% of cases is labelled as secondary hypertension, defined as high blood pressure due to an identifiable cause, like chronic kidney disease, narrowing of the kidney arteries, a hormone-related disorder, or the use of birth control pills. Blood pressure is calculated by two measurements, the systolic and diastolic blood pressures, these are the maximum and minimum pressures, respectively. At rest, normal blood pressure is within the range of 100–140 mm of mercury (mmHg) during systole and 60–90 mmHg diastoles. Hypertension can lead to severe complications including increased risk of heart disease, stroke, and death. Cardiology Meetings will bring together professionals from the fields of Hypertension, Nephrology, Endocrinology, Internal Medicine, Cardiology and more

Track 2: Renal Hypertension

Renovascular hypertension (RVHT) reflects the causal relation between anatomically evident arterial occlusive disease and elevated blood pressure. The coexistence of renal arterial vascular disease and hypertension roughly defines this type of nonessential hypertension. More specific diagnoses are made retrospectively when hypertension improves after intravascular intervention. At present, no sufficiently accurate, non-invasive, radiologic, or serologic screening test is available that, if negative, completely excludes the presence of renal artery stenosis (RAS). This session mainly accounts for the assorted causes and symptoms of reno vascular high blood pressure, alongside of its pathological process, diagnosis and treatment. Now it can be diagnosed by physical examination and imaging. High pressure is dangerous partially as a result of the patients usually don't expertise the symptoms, thus organ injury will occur slowly while not being recognized. Varied techniques are developed to diagnose excretory organ high blood pressure victimization digital image process of radiographs. Hypertension Conferences provides participants and speakers alike with the unique opportunity to debate the most pressing issues in diabetes, obesity and hypertension

Track 3: Pulmonary Hypertension

Pulmonary hypertension (PH) is a rise of blood pressure within the artery, vein, or respiratory organ capillaries, resulting in shortness of breath, dizziness, fainting, leg swelling and different symptoms. This type of hypertension that affects the arteries in the lungs and the right side of your heart, then it begins when tiny arteries in your lungs, called pulmonary arteries, and capillaries become narrowed, blocked or destroyed. This makes it harder for blood to flow through your lungs, and raises pressure within your lungs' arteries. As the pressure builds, your heart's lower right chamber must work harder to pump blood through your lungs, eventually causing your cardiac muscle to weaken and eventually causing the heart muscle to fail. Some forms of pulmonary hypertension are serious conditions that become progressively worse and are sometimes fatal. This session mainly talks about the classification, signs, symptoms and treatments of the Pulmonary Hypertension. The various complications related to pulmonary hypertension are congestive heart failure, blood clotting, liver disease, Lupus, Rheumatoid Arthritis, chronic bronchitis, HIV Associated Pulmonary Hypertension, and PH in Association with Sickle Cell Disease. Cardiology Conferences plan to organize sessions on different aspects of the clinical management of patients with hypertension and related comorbidities

Track 4: Pediatric Hypertension

Obesity has become an increasingly important medical problem in children and adolescents. Primary hypertension is detectable in children and adolescents and, as in adults, is associated with a positive family history of hypertension, obesity, and life-style factors. Among children and adolescents with primary hypertension; the presence of obesity was associated with marked LVH. Most childhood hypertension, particularly in preadolescents, is secondary to an underlying disorder. Renal parenchymal disease is the most common (60 to 70%) cause of hypertension. Adolescents usually have primary or essential hypertension, making up 85 to 95% of cases. The investigations have showed that children in the highest quartile of BP had significantly narrower retinal arterioles than those with lower BP, suggesting that higher BP in childhood is associated with alteration in the microvasculature. There is even emerging evidence that cognitive function is adversely affected by elevated blood pressure in childhood. This session includes the epidemiology, incidence and pathophysiology of pediatric hypertension related with obesity, along with the cardiovascular risk factors, the onset of hypertension and obesity on children and the treatment and management of pediatric hypertension and obesity. Cardiovascular Meetings will have access to a rich, diverse and rewarding scientific program covering many disciplines of prevention and treatment of hypertension and its related diseases and their risk factors

Track 5: Gestational Hypertension

Gestational hypertension or pregnancy-induced hypertension (PIH) is the development of new hypertension in a pregnant woman after 20 weeks gestation without the presence of protein in the urine or other signs of Pre-eclampsia in pregnancy. It is a temporary diagnosis for hypertensive pregnant women who do not meet criteria for preeclampsia or chronic hypertension (hypertension first detected before the 20th week of pregnancy). The diagnosis is changed to, Preeclampsia, if proteinuria or new signs of end-organ dysfunction develop and chronic (primary or secondary) hypertension, if blood pressure elevation persists ≥12 weeks postpartum. The risk factors for Gestational hypertension comprise maternal causes like obesity, past history or adolescent pregnancy, multiple gestations, and family history. There is no specific treatment, but it is monitored closely to rapidly identify pre-eclampsia and its life-threatening complications. Drug treatment options are limited, as many antihypertensive drugs may negatively affect the foetus. During gestational hypertension a women must be offered an integrated package of care, covering admission to hospital, treatment, measurement of blood pressure, testing for proteinuria and blood tests. Hypertension events will undoubtedly bring together elite speakers and distinguished representatives from the scientific, clinical, and business fronts to present leading research and cutting-edge technology in the field of hypertension-related issues.

Track 6: Hypertension & Diabetes

Hypertension can lead to many complications of Diabetes. Most people affected with Diabetes are more prone to suffer Hypertension. Diabetes damages the arteries and make them targets for hardening (also called as atherosclerosis) and if it is not treated then it may also cause blood vessel damage, heart attack, and kidney failure too. In this section of the main we discuss about various types of Diabetes, risk factors that are involved into it, controlling hypertension in patients with Diabetes and Treatment. Heart Congress is open to all healthcare professionals with an interest in cardiovascular disease and high blood pressure

Track 7: Hypertension & Heart Disease

Heart disease describes a range of conditions that affect the heart. Diseases under the heart includes blood vessel diseases, such as coronary artery disease; heart rhythm problems (arrhythmias); and heart defects you're born with (congenital heart defects), among others. Heart disease term is often used interchangeably with the cardiovascular disease. It generally refers to conditions that involve narrowed or blocked blood vessels that can lead to a heart attack, chest pain (angina) or stroke. Other heart conditions, such as those that affect your heart's muscle, valves or rhythm, also are considered of heart disease. Many forms of heart disease can be prevented or treated with healthy lifestyle choices. Heart disease is the study of the effects of drugs on the entire cardiovascular system, which includes the heart and blood vessels. The various complications to related to diabetes are Cerebrovascular disease, Inflammatory, Hypertensive heart disease, Ischemic, Rheumatic heart disease, Acute heart failure and Heart transplantation. Cardiology Meetings will bring together professionals from the fields of Hypertension, Nephrology, Endocrinology, Internal Medicine, Cardiology and more

Track 8: Hypertension, Stroke & Obesity

Stressful situations can lead the blood to spike up temporarily but sometimes it may cause high blood pressure too. Research is still in progress to find out about it. According to some reports the change in the blood pressure behaviour can be due to various habits like overeating, drinking or poor sleeping. It’s possible that health conditions related to stress like anxiety, depression and isolation from friends and family may lead to a heart disease but not to a high blood pressure condition. Some hormonal changes may damage your arteries leading towards heart disease. Hypertension refers to the pressure that blood applies to the inner walls of the arteries. Obesity increases the chances of cardiovascular disease. The individual session in this focuses on obesity-related , its interaction with the outcomes of hypertension, risk factors, treatment and management of cardiovascular disease. Obesity-associated arterial hypertension is characterized by activation of the sympathetic system, activation of the renin-angiotensin system, and sodium retention, among different abnormalities. It's calculable that excess weight, accounted for about twenty sixth of cases of cardiovascular disease in men and twenty eighth in ladies, and for about twenty third of cases of coronary cardiovascular disease in men and 15 % in ladies. Cardiology Symposia plan to focus on different aspects of the clinical management of patients with hypertension and related comorbidities

 Track 9: Hypertension Risk Factors

High Blood Pressure has many causative factors such as age, race, family history, obesity, not being physically active, consuming tobacco, too much salt (sodium) in diet, too little potassium and vitamin D in diet, drinking too much alcohol, stress and certain chronic conditionsThere are general risk factors that can be responsible for raising anyone's risk of hypertension. Although high blood pressure is most common in adults, children may be at risk, too. For some children, high blood pressure is caused by problems with the kidneys or heart. But for a growing number of kids, poor lifestyle habits, such as an unhealthy diet, obesity and lack of exercise, contribute to high blood pressure. Sometimes pregnancy contributes to high blood pressure, as well. Certain diseases and medications are specific causes of high blood pressure. Cardiovascular disease represents the leading cause of morbidity and mortality in Western countries, and hypertension-related cardiovascular events or hypertensive emergencies affect about 37 million people per year, worldwide. In this perspective, hypertensive patients are at increased risk to experience cardiovascular events during life-long period, and treatment of high blood pressure represents one of the most effective strategies to reduce global cardiovascular risk. Hypertension Meetings 2018 promises to offer an exciting scientific program with various experiences such as plenary lectures, meet the expert sessions, award presentations, workshops and industry symposia, etc.

Track 10: Hypertension Diagnosis

Hypertension, or high blood pressure, is the leading risk factor associated with death in the world but is largely asymptomatic and often undetected in patients. Hypertension is typically asymptomatic and only detected through opportunistic screening. Symptoms only manifest when blood pressure reaches very high levels (usually >200 mmHg systolic), and can include headache, dizziness and nose bleeding. It is usually diagnosed when a patient’s blood pressure is repeatedly found to be 140/90 mmHg or higher in a clinical setting and average readings taken using ambulatory blood pressure monitoring or monitoring at home are higher than 135/85 mmHg. Once hypertension has been diagnosed, further tests should be conducted, including urine testing, blood tests, an eye examination and a 12-lead electrocardiogram (ECG).Primary hypertension, in which no specific cause is found, affects 95% of patients. Blood pressure is determined by the cardiac output balanced against systemic vascular resistance. The process of maintaining blood pressure is complex, and involves numerous physiological mechanisms, including arterial baroreceptors, the renin–angiotensin–aldosterone system, atrial natriuretic peptide, endothelins, and mineralocorticoid and glucocorticoid steroids. Heart Conferences will have access to a rich, diverse and rewarding scientific program covering many disciplines of prevention and treatment of hypertension and its related diseases and their risk factors

Track 11: Pharmacological Treatments for Hypertension

Medications to treat high blood pressure includes Thiazide diuretics, Beta blockers, Angiotensin-converting enzyme (ACE) inhibitors,  Angiotensin II receptor blockers (ARBs),  Calcium channel blockers and Renin inhibitors. Additional medication sometimes used to treat high blood pressure comprises Alpha blockers, Alpha-beta blockers, Central-acting agents, Vasodilators and Aldosterone antagonists. No matter what medications a doctor prescribes to treat high blood pressure, lifestyle changes are required to lower blood pressure. Eating a healthier diet with less, exercising regularly, quitting smoking, limiting the amount of alcohol, maintaining a healthy weight or losing weight must be followed up to control high blood pressure. Hypertension events will undoubtedly bring together elite speakers and distinguished representatives from the scientific, clinical, and business fronts to present leading research and cutting-edge technology in the field of hypertension-related issues

Track 12: Nursing Management of Hypertension

Nursing service administration is a coordinated activity, which provides all the facilities necessary for the rendering of nursing service to clients. Nursing service administration is the system of activities directed toward the nursing care of clients, and includes Nursing Leadership and Management the establishment of over-all goals and policies within the aims of the health agency and provision of organization, personnel, and facilities to accomplish this goals in the most effective and economical manner through cooperative efforts of all members of the staff, coordinating the service with other departments of the institution. Nursing service administration is the provision for continuous individual, group and community service, including whatever is necessary. In addressing the factors, which determine health, and to bring them back to self-directive activity towards their own health. The subsidiary objectives of this role are the professional activities of administration, including human relations, communications, teaching, research, and personal development, designed to further the primary objective-the optimum nursing care of patients. In this lecture note management and administration are used interchangeably. Threshold for Initiation of Treatment and Target Values, Assessment and Development of a Lifestyle Treatment plans are the major criteria for nursing management. Cardiac Nursing Meetings is open to all healthcare professionals with an interest in cardiovascular disease and high blood pressure

Track 13: Hypertension Epidemiology

Hypertension is a powerful risk factor for fatal and nonfatal cardiovascular disease events. Data from observational studies indicate that this risk is continuous, without evidence of a threshold, down to blood pressures as low as 115/75 mm Hg. Randomized controlled trials have convincingly shown that treatment of hypertension reduces the risk of stroke, coronary heart diseasecongestive heart failure, and mortality. Various studies of hypertension control have been performed in a variety of epidemiological and practice settings. Despite the recognition that diabetic persons are at especially high risk of cardiovascular disease, studies suggest that hypertension is as poorly controlled in diabetic persons as it is in non-diabetics. Chronic kidney disease represents another comorbidity associated with both difficult blood pressure control and high cardiovascular risk. Various patient characteristics have been associated with uncontrolled hypertension, including age, obesity, and lack of exercise. These characteristics are risk factors for hypertension itself and presumably contribute directly to difficult blood pressure control. Hypertension Conferences provides participants and speakers alike with the unique opportunity to debate the most pressing issues in diabetes, obesity and hypertension

 

ME Conferences is glad to invite you to the upcoming 7th International Conference on Hypertension & Healthcare planned to be held in the beautifully crafted city Helsinki, Finland during June 10-11, 2019. The conference emphasizes the theme Exploring the new horizons to cure Hypertension & Cardiac diseases”.  Hypertension Meeting 2019 welcomes the innovative strategies in the area of hypertension research and also proposes a unique opportunity for the explorers from all over the world to gather, share and perceive new scientific interactions upon the various perceptions of hypertension.

Conference Series Ltd organizes 600+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Conference Highlights:

  •   Hypertension
  •    High Blood Pressure and Kidney Diseases
  •    Pulmonary Hypertension
  •    Gestational Hypertension
  •    Hypertension and Stroke
  •    Hypertension and Diabetes 
  •    Hypertensive Heart Disease
  •    Evaluation of Hypertension
  •    Causative Factors, Risk Assessment and Complications
  •    Diagnosis and Pathophysiology of Hypertension
  •   Anti- Hypertensive Medications
  •   Hypertension Therapy Devices
  •   Diet and Lifestyle in Hypertension Management
  •   Nursing Management of Hypertension
  •   Advanced Treatment Approaches
  •   Clinical Trials and Case Reports
  •   Cardiologists training and education

Importance and scope:

Hypertension is a major risk factor for cardiovascular diseases, cerebrovascular events and ischaemic heart diseases, so is therefore one of the most important preventable causes of premature morbidity and mortality in developed and developing countries. It is often symptomless, so screening is vital before damage is done. Many surveys continue to show that hypertension remains underdiagnosed, undertreated and poorly controlled. Overall, the prevalence of hypertension (at least ≥140/90 mm Hg or on treatment) in those aged over 35 was observed to be 32% in men and 27% in women.

A prospective survey of patients in 20th century electrocardiography, preventive cardiology and the Framingham Study, lipid hypotheses and atherosclerosis, coronary care units, thrombolytic therapy, cardiac catheterization and coronary angiography, open-heart surgery, automatic implantable cardiac defibrillators, and coronary angioplasty. In hypertension, different changes made to the understand the basic levels of blood pressure and in the development of new diagnostic and therapeutic techniques.

Hypertension Meeting 2018 is an international platform for presenting research about Hypertension and related concepts, sharing alternative ideas about the severe cardiovascular risk factor, contributing to the dissemination of information about the trouble for the welfare of the society.

Overall Prevalence of Hypertension Globally

 
              
 

Why Helsinki?

Helsinki is forenamed to be the finest created place for the field of cardiology. Finnish Cardiac Society, Finnish Heart Association and Finnish Hypertension Society in Helsinki is the most found of cardiology research and prominent in field of cardiology.

Why to attend?

Encounter the target market with members from across the globe, committed to learn about hypertension treatment and management. This is the best opportunity to outreach the largest gathering of participants from around the world. Conduct presentations, distribute and update knowledge about the current situation of hypertension treatment and receive name recognition at this 2-day event. World-eminent speakers, most recent researches, latest treatment techniques and the advanced updates in Hypertension Treatment and Management are the principal features of this conference.   

Members Associated With Hypertension:

Hospitals Associated with Hypertension

Helsinki Hospitals:

·         Oulun yliopistollinen sairaala

·         Helsinki Hospital

·         Eiran sairaala ja lääkäriasema

·         HYKSin Oy

·         Meilahden tornisairaala - Meilahti Tower Hospital

 

Finland Hospitals:

·         Helsinki Hospital

·         Meilahden tornisairaala - Meilahti Tower Hospital

·         Eiran sairaala ja lääkäriasema

·         Helsingin Sydänsairaala Oy

·         HYKSin Oy

·         HUS

·         Aurora Hospital

·         Lastenklinikka - Children's Hospital

·         Haartman Hospital

·         Malmin sairaala ja päivystys Helsingin kaupunki

·         HUS Yhtymähallinto, Hallintokeskus, rakennus

 

Globe:

·       North-western Memorial Hospital

·       Hospitals of the University of Pennsylvania-Penn Presbyterian

·       Mount Sinai Hospital

·       University of Michigan Hospitals and Health Centers

·       Duke University Hospital

·       Brigham and Women's Hospital

·       Barnes-Jewish Hospital

·       UCLA Medical Center

·       Stanford Health Care-Stanford Hospital

·       Heart Hospital Baylor Plano

·       Houston Methodist Hospital

·       Loyola University Medical Center

·       NYU Langone Medical Center

·       UPMC Presbyterian Shadyside

·       Scripps La Jolla Hospitals

·       Ohio State University Wexner Medical Center

·       UCSF Medical Center

·       Sentara Norfolk General Hospital-Sentara Heart Hospital

·       Texas Heart Institute at Baylor St. Luke's Medical Center

·       Beaumont Hospital-Royal Oak

·       Minneapolis Heart Institute at Abbott Northwestern Hospital

·       Vanderbilt University Medical Center

·       Memorial Hermann-Texas Medical Center

·       University of Alabama at Birmingham Hospital

·       University of Colorado Hospital

·       St. Francis Hospital

Hospitals Associated with Hypertension:                                               

                                      

Major Societies related to Hypertension:

Finland:

       Finnish Cardiac Society

Finnish Heart Association

Finnish Hypertension Society

Finnish Medical Society Duodecim

Finnish Society of Nuclear Medicine

      The Finnish Association for Heart Children and Adults

Globe:

·         St. Lucia Diabetes & Hypertension Association (SLDHA) 

·         British Hypertension Society

·         American Society of Hypertension

·         Pulmonary Hypertension Association

·         American Heart Association's Council on Hypertension

·         Pulmonary Vascular Research Institute

·         International Society of Hypertension

·         European Society of Cardiology

·         Argentine Society of Hypertension

·         Asian Pacific Society of Hypertension

·         Austrian Society of Hypertension

·         Belgian Hypertension Committee

·         Belorussian Hypertension League

·         Botswana - Heart Foundation of Botswana

·         Brazilian Society of Hypertension

·         Bulgarian Hypertension League

·         Cameroon Cardiac Society

·         Chinese Hypertension League

·         Council for High Blood Pressure of the Irish Heart Foundation

·         Council for the High Blood Pressure Research of the AHA

·         Croatian Society of Hypertension

·         Danish Hypertension Society

·         Egyptian Hypertension Society

·         Estonian Society of Hypertension

·         European Council for Cardiovascular Research

·         European Society of Hypertension

·         French Society of Hypertension

·         German Hypertension Society

·         Hellenic Society for the Study of Hypertension

·         High Blood Pressure Research Council of Australia

·         Hong Kong College of Cardiology

·         Inter-American Society of Hypertension

·         Israeli Society of Hypertension

·         Italian Society of Hypertension

·         Japanese Society of Hypertension

·         Korean Society of Hypertension

·         Latin American Society of Hypertension

·         Libyan Cardiac Society

·         Lithuanian Hypertension Society

·         Malaysian Society of Hypertension

·         Norwegian Society of Hypertension

·         Pakistan Hypertension League

·         Pulse of Asia

·         Russian Antihypertensive League

·        Serbian Society of Hypertension                                          

                      

 

Target Audience:

Our Organization would be privileged to welcome the Directors, Heads, Deans, Professors, Scientists, Researchers, Doctors and Writers of the Hypertension or Cardiology and related departments, Founders and Employees of the related companies, Associations, organizations, laboratory members and Students working in the field of hypertension treatment and management.

Top Universities Finland:

       University of Helsinki

Institute for Molecular Medicine Finland

Academic Medical Center Helsinki

University of Oulu

University of Tampere

University of Turku

·         

Globe:

·         University of Rochester Medical Center

·         Tulane University - School of Medicine

·         University of Chicago Medical Center

·         Yale University

·         University of Pennsylvania in Philadelphia

·         Stanford University in Stanford

·         University of Michigan

·         University of Texas South-western Medical Center

·         University of Washington

·         University of Minnesota Medical Center

·         University of Valencia

·         University of Milano-Bicocca

·         Duke University School of Medicine

·         University of Padua

·         University of Barcelona

·         University of Florence

·         University of Florence

·         University Hospital Maastricht

·         University of Athens

Top Universities Associated with Hypertension:

Industries Associated with Hypertension
 
                            
 
Industries Associated with Hypertension
Finland:
Accord Healthcare Oy

Actavis Oy

Actelion

Allergan Finland

Amgen Ab

Ashfield Nordic OY

Astellas Pharma A/S filial i Finland

Astra Zeneca Oy

Bayer Oy

Biogen

BN Products & Services Ab Oy

Boehringer Ingelheim Finland Ky

CGI Suomi Oy

Eisai AB filial i Finland

Farenta Oy

Farmania Oy

Faron Pharmaceuticals Oy

Fermion Oy

Gilead Sciences Finland Oy

Handico Finland Oy

Janssen-Cilag Oy

Kasve Oy

Krka Finland Oy

Mediq Suomi Oy

Mobidiag

Montisera Ltd.

Mylan Oy

No reviews · Pharmaceutical Company

Novartis Finland Oy

Novo Nordisk Farma Oy

Oriola Oy

Oriola Oyj

Orion Oyj

Oy Becton Dickinson

Oy Eli Lilly Finland Ab

Oy Pharma Nord Ab

Paras Biopharmaceuticals Finland Oy,

Pfizer Oy

Pharmatest Services Ltd

Pharmatory Oy

Pharmia Oy

Primex Pharmaceuticals Oy

Replicon Health Oy

Repolar Pharmaceuticals Oy

Roche Oy

Servier Finland Oy

Suomen Bioteekki Oy

Takeda Pharmaceutical Company

Tamro Oyj

TILT Biotherapeutics

UCB Pharma Oy Finland

Wansår Corporation Oy

Zimmer Finland Oy

 

Globe:

·         Novartis

·         Co. Schering

·         AstraZeneca

·         Generic

·         GlaxoSmithKline

·         Biogen Idec

·         Gilead Sciences, Inc.

·         Boehringer Ingelheim

·         Micardis® 

·         Metalyse® 

·         Lupin Limited

·         Sanofi S.A.

·         Johnson & Johnson Ltd.

·         Pfizer, Inc.

·         Ranbaxy Laboratories Limited

·         Merck & Co., Inc.

·         Astra Zeneca Plc

·         Daiichi Sankyo Company Limited

Industries Associated with Hypertension:

                  

Global Market Value on Hypertension:

 
                          
 

Market Growth of Hypertension Research in the last and upcoming Years:

 
                                                            
 

Global Market at a Glimpse:

High blood pressure or hypertension is the most important risk factor for cardiovascular disease. In over 90% of cases there may be no identifiable cause of hypertension, in which case the condition is known as essential hypertension. The remaining 10% of cases, hypertension may be secondary in nature as a consequence of another medical problem, such as kidney disorders, adrenal tumours, or some drugs.

The prevalence of hypertension is forecasted to grow from 234 million in 2010 to 246 million in 2016 across the seven major markets (France, Germany, Italy, Spain, UK, US, and Japan). In 2016, the US is still expected to be the largest market for hypertension, with an anticipated 83 million sufferers, followed by Japan at 49 million. According to the International Society of Hypertension, there is a clear recognition of hypertension as a major public health issue across all the 7MM.

The global cardiovascular market recorded a sale of $170bn in the year 2010 and is set to grow to $187bn in 2016 at a CAGR of 1.6%. The US continued to be the largest market, with a share of 40% of the overall market. Antihypertensives remained the largest drug class in the year 2010, with a global sale of $37.6bn and a global market share of 22%.
The global market for hypertension management devices is a variable and dynamic market that will experience a strong growth through the year 2023 as an increasing number of devices would become available to address a largely unmet clinical needs.

Fund Allotment to Hypertension Research:

The NIH (National Institute of Health) Funding Opportunity Announcement (FOA), funded by the Patient-Centered Outcomes Research Institute (PCORI), funds up to two new patient-centred comparative effectiveness clinical trials, with the goal of comparing alternative, evidence-based ways to reduce inadequate control of hypertension and disparities in outcomes among high-risk populations, including racial/ethnic minority groups, patients with low socioeconomic status (SES), and individuals residing in rural geographical areas with an above average lifetime risk of cardiovascular disease (CVD). This initiative is supported by the Hypertension Disparities Reduction Program Partnership (HDRPP), a research partnership between NHLBI, NINDS and PCORI, with funds provided by PCORI to the NIH.

The fund allotment granted by the NIH is raised up to $21,500,000 worldwide for supporting research works associated with the advances in treatment and management of Hypertension.

Fund Allotment Statistics:

 
Statistics of Physicians, Researchers and Academicians working on Hypertension:

The estimated statistics of the number of physicians, academicians and researchers working upon the advancement in the treatment and management of hypertension are as described in the pie chart here in.

 

                           

Related Societies:

USA:  American Society of HypertensionAmerican Association of Cardiovascular and Pulmonary RehabilitationAmerican Association of Heart Failure NursesAmerican Cardiology AssociationAmerican Society of Echocardiography,  American Society of Nuclear CardiologyAmerican Diabetes Association,  American Stroke Association,  Inter-American Society of Hypertension,  Latin American Society of HypertensionBrazilian Society of HypertensionAmerican Heart Association,  Congenital Cardiac Anaesthesia Society, Primary Care Diabetes Society, Northwest Association of Cardiovascular and Pulmonary RehabilitationHypertension CanadaPulmonary Hypertension AssociationHeart and Stroke Foundation of Canada

EuropeAustrian Heart FoundationBritish Cardiovascular SocietyBritish Heart FoundationBritish Hypertension SocietyIrish Nurses Cardiovascular AssociationEuropean Society of HypertensionEuropean Stroke Organisation,  Albanian Society of CardiologyBosnia and Herzegovina Society of HypertensionBelorussian Scientific Society of CardiologistsBritish Association of Nursing in Cardiovascular CareRussian Antihypertensive LeagueHeart Foundation of Botswana, Hellenic Society of Hypertension,  British Association of Critical Care NursesCardiology Society of SerbiaSwedish Society of HypertensionStroke and Vascular MedicineEstonian Society of Cardiology,  Georgian Society of CardiologyIrish Heart FoundationLuxembourg Society of CardiologyDanish Society of Hypertension, Latvian Society of HypertensionMontenegro Society of CardiologyMoroccan Society of CardiologyNorwegian Society of CardiologySaudi Heart AssociationNetherlands Society of HypertensionPortuguese Society of HypertensionSlovenian Society of CardiologySpanish Society of HypertensionSwedish Society of CardiologyZurich Heart House.

Middle-EastAlgerian Society of HypertensionRussian Society of CardiologyArmenian Cardiologists AssociationEmirates Cardiac SocietySaudi Hypertension Management Society, Gulf Heart AssociationSaudi Association for Pulmonary HypertensionTurkish Society of Cardiology, Saudi Heart Association, Iranian Heart FoundationCyprus Hypertension Society, Egyptian Hypertension SocietyTurkish Society of Hypertension and Renal Diseases, Israel Heart SocietyLebanese Society of Nephrology and HypertensionKuwait Medical AssociationIraqi Hypertension Society

Asia-Pacific:  Asian Pacific Society of HypertensionCameroon Heart Foundation, Vietnam Heart AssociationHigh Blood Pressure Research Council of AustraliaAssociation of Pediatric CardiologyIndonesian Society of HypertensionThai Hypertension Society,  Malaysian Society of Hypertension, The Japanese Society of HypertensionCardiometabolic Heart CongressChinese Society of CardiologyPhilippine Society of HypertensionThe Heart Association of ThailandWorld Heart FederationPhilippine Heart AssociationChinese Hypertension LeagueHong Kong Society of Paediatric Cardiology, Taiwan Society of CardiologyTaiwan Hypertension SocietyThe Japanese Heart Failure Society, Japanese Heart Rhythm SocietyVietnamese Society of HypertensionSingapore Heart Foundation, Macau Cardiology Association

 

Related Conferences: Cardiology Conferences | Cardiology Meetings | Hypertension Conferences | Healthcare Conferences | Hypertension Events

Hypertension 2017

Thanks to all of our wonderful speakers, conference attendees of Hypertension 2017 Conference were our best ever!

2nd International Conference on Hypertension & Healthcare was held during September 11-13, 2017 Amsterdam, Netherlands with the theme “New insights in diagnosis and management for hypertension”. Benevolent response and active participation from the Scientists, Doctors, Professors, Pharmaceutical Industries, Healthcare Industries, Researchers and Students from the fields of cardiology and healthcare who made this event successful.

The meeting was carried out through various sessions, in which the discussions were held on the following major scientific tracks: Hypertension, Hypertension & Obesity, Renal Hypertension, Pulmonary Hypertension, Gestational Hypertension, Hypertension & Stroke, Causative Factors and Risk Assessment, Diagnosis and Pathophysiology of Hypertension, Pharmacologic and Other Treatments for Hypertension, Diet and Lifestyle in Hypertension Management, Hypertension Epidemiology, Advanced Treatment Approaches, Clinical Case Reports

Hypertension 2017 Organizing Committee would like to thank the Moderators of the conference – Dr. Fabiola B Sozzi, University of Milan, Italy and A.J. van Ballegooijen, VU University, The Netherlands

The conference was initiated with a warm welcome note from Honorable guests and the Keynote forum lead by Dr.Michiel Voskuil from Universitair Medisch Centrum Utrecht, The Netherlands and Dr. Attila Kardos from Milton Keynes University Hospital, UK and Igor I Tulevski from Cardiologie Centra Nederland, The Netherlands

The highlights of the meeting were the eponymous lectures, delivered by:

  • Dr. Fabiola B Sozzi, University of Milan, Italy
  • Hossein Tabriziani, Loma Linda University, USA
  • Valéria Paula S. Fazan, University of Sao Paulo, Brazil
  • Nilda Gladys Espinola-Zavaleta, National Institute of Cardiology Ignacio Chavez, Mexico
  • Patricia Hidalgo M, San Ignacio-Pontificia Universidad Javeriana, Colombia
  • Alan Fleming, Optos, UK
  • Louis Peeters, Utrecht University, The Netherlands
  • Marc Spaanderman, Maastricht University, The Netherlands
  • Johannes J. (Hans) Duvekot, Erasmus University, The Netherlands
  • Peter de Leeuw, Maastricht University, The Netherlands
  • Faezeh Sahbaeiroy, Iran
  • Bum Ju Lee, Korea Institute of Oriental Medicine, Republic of Korea
  • A.J. van Ballegooijen, VU University, The Netherlands
  • Fatemeh Esfarjani, Shahid Beheshti University of Medical Sciences, Iran
  • Amar Mohanrao Taksande, Jawaharlal Nehru Medical College, India
  • Soha M Abd El Dayem, National Research Centre, Egypt
  • Ahmed A Battah, Cairo University, Egypt

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums at Hypertension 2017. We sincerely thank the Organizing Committee Members, Editorial Board Members of International Journals, Participants, Attendees and Media Partners for their gracious presence and generous support, without which the conference would not have reached the pinnacle of success. With the unique feedback from the conference, we would like to announce the commencement of the 7th International Conference on Hypertension & Healthcare during June 10-11, 2019 at Helsinki, Finland.

Let us meet again @ Helsinki, Finland

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date June 10-11, 2019
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2
Poster Opportunity Closed Click Here to View

Testimonials